Environmental, Social, Governance

Sanofi’s social impact strategy aims to build a healthier, more resilient world by ensuring access to healthcare for the world’s poorest people, and bringing a much needed focus to the development of treatment for childhood cancer. Integrated into the company’s Play to Win business strategy, Sanofi’s commitment to society will continue the fight against infectious diseases such as sleeping sickness and polio, while accelerating its goals to reduce the environmental impact of its products and its worldwide operations. Key to tackling the global challenges that face society are its people, who each have a role to play in building a diverse and inclusive workplace.

ESG

Our reporting principles are based on the Global Reporting Initiative (GRI) standards, under the “Core” option. Sanofi is also a signatory of the United Nations Global Compact.

  • Sanofi publishes an Integrated Report based on the International Integrated Reporting Council (IIRC) framework. It presents, in a synthetic manner, the Group’s strategy for creating short, mid- and long-term value (financial and extra-financial) for the company and its stakeholders.
  • Sanofi also publishes in its French registration document (Document d’Enregistrement Universel) a chapter on Corporate Social Responsibility (Chapter 4) which includes our Statement of Extra Financial Performance (DPEF). An English translation of this chapter is available below.
  • CSR indicators and the auditors’ report are reported in the factsheet CSR Indicators Table and Auditor’s Report, see below.
  • Other reference documents and factsheets are available in the Document Center of the “Our Responsibility” section (see below).

SASB Index

Quick links

At the heart of Sanofi

Integrated Report 2020

2020 Declaration of Extra-Financial Performance

Woman and smartphone

Access to all factsheets

our value creation

Our value creation

Our contribution to the UN SDG

Recognition for our extra-financial performance

Sanofi’s performance is recognized through our inclusion in the most important international Socially Responsible Investment (SRI) indices including:

  • Dow Jones Sustainability Index (DJSI) World (Bronze Class): reference index in sustainable Development
  • FTSE4Good (Financial Times Stock Exchange)
  • Access to Medicine Index (ATM)
  • Stoxx® Global ESG Leaders indices

Extra-financial performance

SANOFI rankings & scores - 2020/2021
Logo DJSI

DJSI 
Included in 2020 DJSI World for the 14th consecutive year
Included in the DJSI Europe for the 2nd consecutive year


Score 86/100
2nd in ranking among 91 pharmaceuticals companies

Logo MSCI MSCI


Score: BBB
(scale from CCC to AAA)
#5 among the 6 largest
pharmaceutical companies

Logo Sustainalytics Sustainalytics


Score 23.7 Medium Risk
(scale from 0 to 40+ / lower is better)
#13 among
483 pharmaceutical companies

Logo ISS ESG
ISS-ESG


Score: B (Prime status)
(scale from D- to A+)
Among the 3 industry leaders
within 476 pharmaceutical companies

Logo FTSE4Good FTSE4Good
Score: 3.9/5

(Higher is better)

CDP Logo
CDP Climate Change
Score: A-
CDP Water Score: A
Logo ATM Index ATM index 


#5 among
20 pharmaceutical companies

Vigeo Eiris 

Score of 62 out of 100
1st pharmaceutical company out of 57


Contacts

The Corporate Social Responsibility department, in coordination with the Investor Relations department, is in charge of the information analyzed by socially responsible investors and rating agencies which assess companies according to social, environmental, economic and governance criteria.

Sanofi Investor Relations
Tel: +33 (0)1 53 77 45 45
e-mail: investor.relations (at) sanofi.com